Fibrosis is a common complication in chronic liver diseases, leading to scarring and reduced function.
纤维化是慢性肝病的常见并发症，导致组织疤痕形成和功能减退。
Lung
fibrosis results from excessive inflammation and collagen accumulation in the lung tissue.
肺纤维化是由于肺组织过度炎症和胶原蛋白积聚造成的。
Cirrhosis, a form of
fibrosis, can be reversed if caught early enough through medical intervention.
肝硬化（一种纤维化形式）在早期通过医疗干预可以逆转。
The patient's kidney function is severely impaired due to progressive renal
fibrosis.
患者的肾功能因渐进性的肾纤维化而严重受损。
She underwent surgery to treat her interstitial lung disease, which involves lung
fibrosis.
她接受了手术治疗间质性肺病，其中包括肺纤维化。
Fibrosis in the heart muscle can lead to congestive heart failure over time.
心肌纤维化随着时间推移可能导致充血性心力衰竭。
Researchers are studying new therapies to prevent or halt the progression of liver
fibrosis.
研究人员正在研究新的疗法以防止或阻止肝纤维化的进展。
Rheumatoid arthritis can cause
fibrosis in the joints, leading to stiffness and pain.
类风湿关节炎可能导致关节纤维化，引起僵硬和疼痛。
Early detection of hepatic
fibrosis is crucial for effective treatment and management of liver disease.
早期发现肝纤维化对于肝病的有效治疗和管理至关重要。
Long-term exposure to asbestos can lead to pulmonary
fibrosis, a serious respiratory condition.
长期接触石棉可引发肺纤维化，这是一种严重的呼吸系统疾病。
During the CIIE, Boehringer Ingelheim also exhibited a new drug candidate at the Phase-3 clinical trial for treating idiopathic pulmonary fibrosis, a rare and chronic lung disease.
在CIIE期间，勃林格殷格翰还在治疗特发性肺纤维化（一种罕见的慢性肺病）的3期临床试验中展示了一种新的候选药物。
"In the field of human pharma, the company will present innovative products for rare skin diseases, obesity, pulmonary fibrosis, mental health, and cancer at the CIIE.
“在人类制药领域，该公司将在进博会上展示针对罕见皮肤病、肥胖、肺纤维化、精神健康和癌症的创新产品。
"Xu Xiaoyuan, director of the infectious disease department of Peking University First Hospital, said the new non-invasive technology allows doctors to easily and accurately detect liver fibrosis and cirrhosis while traditional invasive methods are not always applicable, which is of great significance for the prevention and treatment of liver disease in China.
Insilico has nominated eight preclinical drug candidates since 2021, which were discovered or designed using its proprietary AI platform in a variety of disease areas, including fibrosis, inflammation and cancer.
Besides, the company's first AI-discovered drug candidate, for the treatment of a rare and chronic lung disease called idiopathic pulmonary fibrosis, has finished dosing subjects for a phase-1 clinical study in China.
For human pharmaceuticals, the company will present innovative products for rare skin diseases, obesity, pulmonary fibrosis, mental health and cancer.
Insilico Medicine, an end-to-end AI-driven drug discovery company with a key research and development team based in Shanghai, announced on Feb 24 it had dosed multiple healthy volunteers in the phase-1 clinical trial to evaluate the safety of ISM001-055, the first anti-fibrotic small molecule inhibitor generated by its AI-powered drug discovery platform for idiopathic pulmonary fibrosis.
The company announced recently that it has found a new therapeutic target and potential therapy candidate for idiopathic pulmonary fibrosis, or IPF, through AI technologies.